Get the Stockscreener App
2.39
2.58%
0.06
Pre-market:
2.39
Black Diamond Therapeutics Inc stock is traded at $2.39, with a volume of 534.21K.
It is up +2.58% in the last 24 hours and down -1.65% over the past month.
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The foundation of companies has been built upon a deep understanding of cancer genetics, onco-protein structure and function, and medicinal chemistry. Its clinical-stage program, silevertinib (formerly BDTX-1535), a brain-penetrant, fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor, is currently being studied in a Phase 2 clinical trial in patients with epidermal growth factor receptor mutant (EGFRm) non-small cell lung cancer (NSCLC). The Company manages its operations as a single operating segment and single reportable segment.
See More
Previous Close:
$2.33
Open:
$2.29
24h Volume:
534.21K
Relative Volume:
0.73
Market Cap:
$136.92M
Revenue:
$70.00M
Net Income/Loss:
$22.37M
P/E Ratio:
6.2829
EPS:
0.3804
Net Cash Flow:
$29.61M
1W Performance:
+12.21%
1M Performance:
-1.65%
6M Performance:
-35.92%
1Y Performance:
+51.27%
1-Day Range:
$2.28
$2.49
1-Week Range:
$2.00
$2.49
52-Week Range:
$1.195
$4.94
Black Diamond Therapeutics Inc Stock (BDTX) Company Profile
Name
Black Diamond Therapeutics Inc
Sector
Industry
Phone
617-417-5868
Address
245 FIRST STREET, 18TH FLOOR, CAMBRIDGE, MA
Compare BDTX vs VRTX, REGN, ARGX, ALNY, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BDTX
Black Diamond Therapeutics Inc
|
2.39 | 136.92M | 70.00M | 22.37M | 29.61M | 0.3804 |
VRTX
Vertex Pharmaceuticals Inc
|
438.71 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
761.85 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
746.42 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
318.85 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
162.43 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Black Diamond Therapeutics Inc Stock (BDTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-03-25 | Downgrade | Guggenheim | Buy → Neutral |
| Nov-18-25 | Resumed | Piper Sandler | Overweight |
| Oct-16-25 | Resumed | Stifel | Buy |
| Sep-04-25 | Initiated | Guggenheim | Buy |
| Jul-01-25 | Resumed | Raymond James | Outperform |
| Jul-31-24 | Initiated | Raymond James | Outperform |
| Jul-14-23 | Initiated | Piper Sandler | Overweight |
| Jun-30-23 | Upgrade | Stifel | Hold → Buy |
| Jun-28-23 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Jun-27-23 | Upgrade | Wedbush | Neutral → Outperform |
| Mar-29-22 | Downgrade | Wedbush | Outperform → Neutral |
| Mar-22-22 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Sep-30-21 | Initiated | Stifel | Hold |
| Jan-07-21 | Initiated | Wedbush | Outperform |
| Nov-24-20 | Initiated | Berenberg | Buy |
| May-04-20 | Initiated | H.C. Wainwright | Buy |
| Feb-24-20 | Initiated | Canaccord Genuity | Buy |
| Feb-24-20 | Initiated | Cowen | Outperform |
| Feb-24-20 | Initiated | JP Morgan | Overweight |
| Feb-24-20 | Initiated | Jefferies | Buy |
View All
Black Diamond Therapeutics Inc Stock (BDTX) Latest News
BDTX Should I Buy - Intellectia AI
Retail Surge: Does Black Diamond Therapeutics Inc align with a passive investing strategy2026 Momentum & Daily Technical Stock Forecast Reports - baoquankhu1.vn
Published on: 2026-03-30 21:41:19 - baoquankhu1.vn
Sentiment Review: Can Black Diamond Therapeutics Inc maintain sales growthTake Profit & Daily Stock Trend Watchlist - baoquankhu1.vn
Analysts Are Bullish on These Healthcare Stocks: Gain Therapeutics (GANX), CG Oncology, Inc. (CGON) - The Globe and Mail
Invesco Dynamic Credit Opportunity Fund's Black Diamond Therapeutics Inc(BDTX) Holding History - gurufocus.com
Wedbush bullish on Black Diamond Therapeutics (BDTX) following progress in Silevertinib program - MSN
Market Review: Is Black Diamond Therapeutics Inc a strong growth stock2026 Biggest Moves & Daily Profit Maximizing Tips - baoquankhu1.vn
Aug Macro: Will Black Diamond Therapeutics Inc benefit from rate cuts2026 Drop Watch & Risk Controlled Swing Trade Alerts - baoquankhu1.vn
Wedbush Bullish on Black Diamond Therapeutics (BDTX) Following Progress in Silevertinib Program - Yahoo Finance
Black Diamond Therapeutics: Market Is Yawning About These Data, But I See Opportunity - Seeking Alpha
Top 5 Stocks Under $5 That Could Triple - Insider Monkey
Technical Analysis: Will Black Diamond Therapeutics Inc benefit from AI trendsQuarterly Profit Report & Weekly Setup with High ROI Potential - baoquankhu1.vn
Volume Summary: Can Black Diamond Therapeutics Inc maintain sales growthDollar Strength & Low Risk High Reward Ideas - baoquankhu1.vn
Exit Recap: Is Black Diamond Therapeutics Inc stock good for income investorsMarket Movement Recap & AI Optimized Trade Strategies - baoquankhu1.vn
Black Diamond (BDTX) director receives 6,919-share stock grant - Stock Titan
Black Diamond Therapeutics (BDTX) director receives 6,105-share stock grant in lieu of cash - Stock Titan
VIX Spike: Is Black Diamond Therapeutics Inc part of any ETFEarnings Trend Report & Low Risk High Reward Ideas - baoquankhu1.vn
EV Market: Is Black Diamond Therapeutics Inc benefiting from interest rate changesQuarterly Profit Review & Technical Pattern Based Buy Signals - baoquankhu1.vn
Stock Ratings | Baird Bank raises CRCL's price target to $138; Rodman & Renshaw initiates coverage of BTAI with a "buy" recommendation and a $17 price target, representing a potential upside of 882.66%. - Sahm
Piper Sandler Sticks to Its Buy Rating for Black Diamond Therapeutics (BDTX) - The Globe and Mail
Analysts Are Bullish on Top Healthcare Stocks: Lantheus (LNTH), Perspective Therapeutics (CATX) - The Globe and Mail
Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
Black Diamond Therapeutics (BDTX) Receives a Buy from TD Cowen - The Globe and Mail
Investment Recap: Does Black Diamond Therapeutics Inc align with a passive investing strategy2026 Setups & Weekly High Potential Alerts - baoquankhu1.vn
Black Diamond Therapeutics (BDTX) Profit Swing To US$0.81 EPS Challenges Bearish Earnings Narratives - simplywall.st
BDTX: Wedbush Raises Price Target, Maintains Outperform Rating | - GuruFocus
Wedbush Forecasts Strong Price Appreciation for Black Diamond Therapeutics (NASDAQ:BDTX) Stock - MarketBeat
Wedbush Lifts Price Target on Black Diamond Therapeutics to $14 From $13, Keeps Outperform Rating - marketscreener.com
Black Diamond: Fourth Quarter Financial Results Overview - Bitget
Black Diamond Therapeutics 2025 Annual Report – Clinical-Stage Oncology Pipeline, MasterKey Therapies, and Regulatory Overview - Minichart
Black Diamond Therapeutics (BDTX) Advances Silevertinib Trials i - GuruFocus
Black Diamond Therapeutics (NASDAQ:BDTX) Issues Quarterly Earnings Results - MarketBeat
Black Diamond: Q4 Earnings Snapshot - kare11.com
BDTX: Strong clinical and financial performance, with silevertinib advancing and cash runway to 2028 - TradingView
Silevertinib data and Servier pact shape Black Diamond (NASDAQ: BDTX) - Stock Titan
Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update - The Manila Times
Black Diamond Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 - marketscreener.com
[8-K] Black Diamond Therapeutics, Inc. Reports Material Event | BDTX SEC FilingForm 8-K - Stock Titan
Cancer drug hitting 60% response rate now funded into 2028 - Stock Titan
Black Diamond Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
BDTX (Black Diamond Therapeutics) NonCurrent Deferred Reven - GuruFocus
DAWN Stock Jumps 66% on $2.5B Buyout Offer From Servier - Finviz
Published on: 2026-03-07 03:01:03 - baoquankhu1.vn
Black Diamond Therapeutics Teases Next-Quarter PFS Data for Silevertinib at TD Cowen Conference - MarketBeat
Is BDTX's Cash balance Enough to Successfully Develop Its NSCLC Drug? - MSN
Downgrade Watch: Whats the profit margin of Black Diamond Therapeutics IncWeekly Market Summary & Real-Time Stock Entry Alerts - baoquankhu1.vn
BDTX: Silevertinib demonstrates robust efficacy in NSCLC and is advancing to pivotal GBM trials - TradingView
Black Diamond Therapeutics Inc at TD Cowen Healthcare Conference Transcript - GuruFocus
Gyre Therapeutics Announces Appointment of David M. Epstein, Ph.D., to Board of Directors - Quantisnow
Black Diamond Therapeutics to Participate in Upcoming Investor Conferences - The Manila Times
Black Diamond Therapeutics Inc Stock (BDTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.49%
1.47%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):